Evaluation of Iron Biomarkers and Haematological Variables in Asymptomatic Individuals Infected by Hepatitis C Virus in Ebonyi State, Nigeria

References

[1] Abayomi Adeoye (2007). Haemopoiesis: Medical Laboratory Practice, 1 st edition184 – 185.

[2] Adams Paul C, Barton James C (2011). A diagnostic approach to hyperferritaemia with a non-elevated transferrin saturation. Journal of Hepatology, 55: 453 – 458.

[3] Agnello V, Chung RT, Kaplan LM (1992). A role of hepatitis C virus infection in type II Cryoglobinaenia. New England of Journal of Medicine, 327: 1490 - 1495.

[4] Alao O, Okwori E, Araoye M (2010). The Sero-prevalence of Hepatitis c virus (HCV) Infection among Prospective Blood Donors in Makurdi, Nigeria. The International Journal of Infectious Disease,8: 1.

[5] AlFaleh F, Ramias (1997) Hepatitis c virus infection in Saudi Arabia: a review. Annual Saudi Medical, 17: 77- 82.

[6] Alfaleh FZ (2015). Strategies to manage hepatitis C virus infection disease burden. Journal of viral hepatitis, 22: 42 – 65.

[7] Alter MJ, Kruson-Moran D, Nainan V (1999). The prevalence of hepatitis c virus infection in the Unger 2ited States. NewEngland Journal of Medicine, 341: 550 – 562.

[8] Araoye MO (2004). Sample size determination Research Methodology with statistics for health and social sciences. Nathadox publishers, 5: 115 -120.

[9] Arjun M, Chaitali M (2015). Understanding the Pathophysiological Basis of Alterations of Haematological picture in Alcohol Abuse Patients. Journal of Medical and Health Sciences, 4(4): 1 – 5.

[10] Arrese M, riquelme A, Soza A (2010). Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Annual Hepatology,9: 112 – 118.

[11] Ayolabi CI, Taiwo MA, Omilabu SA, Abebisi Ao, Fatobi OM (2006). Sero-prevalence of hepatitis c virus among blood donors ILagos, Nigeria. African Journal of Biotechnology,5(20): 1944 - 1946.

[12] Baker C, Hall R, Gazziano JM, Gagnon D, Bzowej N (2001). Prevalence and risk factors for hepatitis C virus infection at an urban Veteran Administration Medical Centre. Hepatology,34:1200 – 1205.

[13] Bartenschlager R, penin F, Lohmann V, Andre P (2011). Assembly of infections hepatitis C virus particles. Trend of Microbiology, 19:95 - 105.

[14] Beld M, Habibuw MR, Rebers SP, Boom R, Reesink HW (2000). Evaluation of automated RNA-extraction technology and a qualitative HCV assay for sensitivity and detection of HCV RNA in pool -screening systems. Transfusion, 40: 579 – 800.

[15] Bell A, Skinningsrud N, Raknerud K (1994). “Serum ferritin and transferrin saturation in patients with chronic alcoholic and non- alcoholic liver diseases “.InternationalJournal of Medicine, 236(3): 315 - 322.

[16] Benova Lenka, Yousra Mohamoud A, Clara Calvert, Laith Abu-Raddad J (2014). Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis. Clinical Infectious Diseases, 1: 10.

[17] Berengher (2000). HCV-related fibrosis progression following liver transplantation increase in recent years. Journal of Hepatology, 32(4): 673 -684.

[18] Bieche I, Asselah T, laurendeau I, Vidand D, Degot C, Paradis V, Bedossa P, Valla DC, Marcelli P, Vidand M (2005). Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis c virus infection. Virology, 332: 130 -144.

[19] Blumberg BE, Lustbader ED, Whitford PL (1981). “Changes in serum iron levels due to infection with hepatitis B virus”National Academic Science USA, 78 (5): 3222 – 3224.

[20] Bo Q, Orsenigo R, Wang J,Griffel L, Brass C (2015). Glucose abnormalities in Asian patients with chronic hepatitis C. Drug Developmental therapy; 6009.

[21] Boige V, Castera L, de Roux N, Ganne-Carrie N, Ducot B, Pelletier G (2013). Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut, 52: 1178 –1181.

[22] Bonkovsky H. L (2002). “Iron as a commorbid factor in chronic viral hepatitis”. American Journal of Gastroenterology,197 (1): 1 –4.

[23] Bonkovsky H.L, Troy N, McNeal K, Banner B.F, Sharma A, Obando J, Mehta S, Koff RS, Liu Q, Hsieh C.C (2002). “Iron and HFE or TFR1 mutation as commorbid factors for development and progression of chronic hepatitis C. Journal of Hepatology, 137(6): 848 – 854.

[24] Bonkovsky H.L,BannerB.F, Lambrecht R.W, Rubin R.B (1996). Iron in liver disease other than haemochromatosis. Liver Diseases, 16: 65 – 82.

[25] Bradley D.W, McCaustland K.A, Cook E.H, Schable C.A, Ebert J.W, Maynard J. E (1985). Post transfusion non-A, non-B hepatitis in chimpanzees. Gastroenterology,88: 773 – 779.

[26] Briggs M.E, Baker C, Hall R, Gazziano J.M, Gagnon D, Bzowej N (2001). Prevalence and risk factors for hepatitis C virus infection at an urban veterans administration medical Centre. Hepatology, 34: 1200 – 1205.

[27] Brito-Babapulle F (2003). The eosinophihas including the idiopathic hypersinophilic syndrome. British Journal of Haematology,12:203-223.

[28] Bronowicki JP, Venard V, Botte C (1997). Patient to patient transmission of hepatitis C virus during colonoscopy. New England Journal of Medicine,33:237-241.

[29] Busch MP, Wilber JC, Johnson P, Tobler L, Evans CS (1992). Impart of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion, 32: 420 – 425.

[30] Buyukasik N. S, Nadir I, Akin F. E, Cakal B, Kav T, Ersoy O (2011). Serum iron parameters in cirrhosis and chronic hepatitis: detailed description. Turkish Journal of Gastroenterology, 22: 606 – 611.

[31] Catanese MT, Domer M, (2015). Advances in experimental systems to study hepatitis C virus in vitro and in vivo. Virology, 479: 221 – 233.

[32] Centre for Disease Control and Prevention (2017). Hepatitis C virus Frequent Asked Questions for Health Professionals. Retrieved on January 10, 2018,from https:// www.cdc.gov/hepatitis/hcv/hcvfaq.htm

[33] Centres for Disease Control and prevention (2012). CDC Health Information for International Travel. New York: Oxford University Press. Available from: hpp://wwwnc.cdc.gov/travel/page/yellowbook .

[34] Chamberlain R, Adams N, Saced A, Sim monds P, Elliot R (1997). Comlete nudeostide sequence of a type 4 hepatitis c virus variant. The predominant genotype in the Middle East. Journal of General Virology,78: 1341 – 1347.

[35] Chandok N, Nimuk G, Wengiel M, Ubanova J (2012). “Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease. Journal of Gastroenterology and Liver Diseases, 21(1): 53 – 58.

[36] Chen H, Attieh ZK, Dang T, Huang G, Van der Hee RM, Vulpe C (2009). Decreased hephaestin expression and activity leads to decreased iron efflux from differentiated cells. Journal of Cell Biochemistry,107: 803-808.

[37] Choo QL, Kuo G, Weiner AJ, Overky LR, Bradley DW, Houghton M (1989). Isolation of a DNA done derived from a blood-borne run- A, run-B viral hepatitis genome. Science, 244: 359 – 362.

[38] Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C (1991). Genetic Organization and diversity of the hepatitis c virus. National Academic of Science USA, 88: 2451 – 2455.

[39] Conm-Cantilena C, VanRaden M, Gibble J, Melponder J, Shakil Ao, Viladomiu L (1996). Rintes of infection, virennia, and liver disease in blood donors found to have hepatitis C virus infection. New England Journal of medicine,334:1691 - 1696.

[40] Conti F, Bounfiglioli F, Scuteri A (2016). Early occurrencJ and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated direct-acting antivirals. Journal of Hepatology, 65: 727 – 733.

[41] Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F (1995). High hepatitis C virarmia and impaired antibody response in patients coinfected with HIV. Journal of Hepatology,9:1131 – 1136.

[42] D’Souza RF, Feakins R, Mears L, Sabin CA, Foster GR (2005). “Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C”. Alimentary Pharmacology therapy, 21(5): 519 – 524.

[43] Davis GL, Balart LA, Schiff ER (1989). Treatment of chronic hepatitis C with recombinant interferon alpha: a multi center randomized, controlled trial. New England Journalof Medicine, 321: 1506 – 1510.

[44] De Re V, De Vita S, Marzotto A, Gloghini A, Pivetta B, Gasparotto P, (2000). Pre-malignant and malignant lymphoproliferations in an HCV – infected type 11 mixed cryoglobulinaemic patients are sequential phases of an antigen – driven pathological process. International Journal of Cancer, 87: 211 – 216.

[45] De Zoysa M, Lee J (2007). “Two ferritin subunits from disk abalone (Haliotis discus discus): doning, characterization and expression analysis”. Fish and Shellfish Immunology,23(3): 624 – 625.

[46] Desenchos JC (2000). Epidemiology of hepatitis C. Review, 50: 1066 – 1070.

[47] Dicky W (2002). Iron deficiency, gastric atrophy, and Helicobater pyloric. Liver Diseases,34: 13 – 15.

[48] Douam F, Lavillete D, Cosset FL (2015). The mechanism of HCV entry into host cells. Prognostic Molecular Biology,129: 63 – 107.

[49] Duffell E. F., Hedrich D, Mardh O, Mozalevskis A (2017). Towards elimination of hepatitis B and C in European Union and European Economic Area Countries: Monitoring the world Health Organization global health sector strategy core indicators and scaling up key intervention. Eurosurveillance, 22(9): 30476.

[50] EASL International Concensus Conference on Hepatitis C (1999). Consensus Statement – European Association for the study of the liver. Journal of Hepatology,30(5): 956 – 961.

[51] Eck MV, (2008). Scavanger receptor Bi facilitates the metabolism of VCDC lipoproteins in Vivo. Journal of Lipid Resources, 49: 136-146.

[52] Edwards DJ, Coppens DG, Prasad TL, Rook LA, Lyer JK (2015). Access to hepatitis C medicines. World Health Organization Bulletin, 93(11): 799 – 805.

[53] Ejiofor O. S., Ibe B. C., Enodi I. J (2009). The Role of Blood Transfusion on the prevalence of Hepatitis C Virus Antibodies in children with sickle cell Anaemia in Enugu, South East Nigeria. Nigerian Journal of clinical practice 12: 355 - 358.

[54] Elsayed ME, Stack AG (2016). Transferrin Saturation: A Body Iron Biomarker. Advances in Clinical Chemistry, 75: 71 – 97.

[55] Esfahani SHZ, Kardi MT, Edalati M (2010). Hepatitis C virus genotype frequency in Isfaham province of Iran: a descriptive cross- sectional study. Journal of Virology, 7: 69 – 75.

[56] European Association for the Study of the Liver (2016). EASL Recommendations on Treatment of Hepatitis C. Journal of Hepatolog,66: 153 – 194.

[57] European Association for the Study of the Liver (2018). EASL Recommendations on Treatment of Hepatitis C. Journal of Hepatology, 1 – 51.

[58] European Union HCV Collaborators (2017). Hepatitis C virus prevalence and level of intervention required to achieve the WHO target for elimination in the European Union by 2030: a modeling study. Gastroenterology and Hepatology, 2: 325 – 336.

[59] Eyster ME, Diamondstone LS, Lien JM (1998). Natural history of hepatitis C virus in multitransfused hemophilic. Effect of co- infection with human immune deficiency virus. Journal of Acquire Immune Deficiency Syndrome, 6: 602 – 610.

[60] Fafari S, Copes R, Baharlou S, Eliminan M, Buxton J (2010). Tattooing and the risk of transmission of hepatitis c: a systematic review and meta-analyses. International Journal of Infectious Disease,14(2): 928 – 940.

[61] Fakeeh M, Zaki AM (1999). Hepatitis c: prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia. American Journal of Tropical Medical Hygiene, 61: 889 – 892.

[62] Farci P, Alter HJ, Shimoda A (1996). Hepatitis C virus associated fulminant hepatitis failure. England Medical Journal, 335: 613 – 634.

[63] Fargions S, Fracanzani AL, Rossini A (2002). Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C. American Journal of Gastroenterology,97: 1204 – 1210.

[64] Farnaud S, Evans RW (2003). Lactoferrin –a multifunctional protein with antimicrobial properties. Molecular Immunology, 40: 395 – 405.

[65] Fasola FA, Otegbayo JA, Abijah UMA, Ola S (2009). Haematological parameters in Nigerians with acute hepatitis. Nigerian Journal of Gastroenterology and Hepatology, 1(1): 27 – 31.

[66] Federal College of Agriculture, Ishiagu (2014). Retrieved on March 20.

[67] Flint M, Maidens C, Loomis-price LD, Shotton C, Dubuisson J, Monk P (1999). Characterization of hepatitis c virus E2 glycoprotein interaction with a putative cellular receptor, CD81. Journal of virology, 73: 6235-6244.

[68] Forton DM, (2006). Hepatitis c – The brain strain. Liver InternationalJournalof Hepatology, 36: 1415 - 1417.

[69] Foster DA (2007). Regulation of MTOR by phosphatidic acid? Cancer Resources,67: 1 – 4.

[70] Friedrich-Rust M, Zeuzem S, Sarrazin C (2007). Current therapy for hepatitis C. International Journal of Colorectal Disease, 22(4): 341 – 349.

[71] Fujita N, Sugimoto R, Ma N, Tanaka H, Iwasa M, Kobayashi Y, watanable S, Kaito M, Takei Y (2008). Comparism of hepatic oxidative DNA damage in hepatitis B and C. Journal of viral hepatology,15: 498 – 507.

[72] Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T (2003). L-SIGN (CD 209L) is a Liver-specific capture receptor for hepatitis c virus. Procedure National Academic Science USA, 100: 4498 – 4503.

[73] Geijlenbeek TBH, Kwon DS, Forensma R, Vliet SJV, Van Duijnhoven GCF (2000). A dendritic cell-specific HIV- binding protein that enhances trans-infection of T cells. Cell, 100: 587.

[74] Ghany MG, Stranger DB, Thomas DL, Seff LB (2009). Diagnosis, Management and treatment of hepatitis C: An update. Hepatology, 49 (4): 1335 – 1374.

[75] Godwin I, Achinge, Abraham O, Malu, Peter T, Mbaave, Terkaa T, Vivian N, Hameed Mohammed, Michael A (2013). Prevalence of Hepatitis C in Makurdi, North Central Nigeria. Journal of Dental and Medical Science, 7(5): 6 -10.

[76] Golden-Mason L, Rosen HR (2013). National killer cells: multifaceted players with key roles in hepatitis c immunity. Review of Immunology, 255: 68 – 81.

[77] Haid S, Grethe C, Dill MT, Heim M, Kaderali L, Pietschmann T (2013). Isolate-dependent use of claudins for cell entry by hepatitis C virus. Hepatology, 7: 30 – 39.

[78] Halim NK, Ajayi OI (2000). Risk factors and sero-prevalence of Hepatitis C antibody in blood donors in Nigeria. African Medical Journal, 77: 410 – 420.

[79] He LF, Alling D, Popkin T, Shapiro M, Alter HJ, Purcell RH (1987). Determining the size of non-A, non-B hepatitis virus by filtration. Journal of Infectious Diseases, 156: 636 – 640.

[80] Health Library (2017). Facts about Blood. Johns Hopkins Medicine. Accessed: 16 September, 2017.

[81] Henry JB (1984). Clinical Diagnosis and Management by Laboratory Methods. Philadelphia. W.B. Saunders. 1434

[82] Hiam Chemaitelly, Laith J, Abu-Radded, Silva p, Kouyoumjian (2018). Characterizing hepatitis c virus epidemiology in Egypt: Systematic reviews, meta-analyses, and meta- regression. Scientific Reports, 8: 1661.

[83] Hijikata M, Kato N, Obtsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K (1991). Hyperviable regions in the putative glycoproteins of hepatitis c virus. Biochemistry and Biophysics, 175: 220 – 228.

[84] Hoffbrand A. V, Moss P. A (2011). The White Cells, Granulocytes, Monocytes and their benign disorders: Essential Haematology, 6 th edition, WILEY-BLACKWEL. 94 – 95.

[85] Holland Wl, Summers SA (2008). Sphingolipids, insulin resistance, and metabolic disease: new insights from a vivo manipulation of sphingolipid metabolism. Endocrinology Review, 29: 381 - 402.

[86] Honda M, Ping LH, Rijnbrand RC, Amphlett E, Clarke B, Rowlands D, Lemon SM (1996). Structural requirements for initiation of translation by internal ribosome entry within genome – length hepatitis C virus RNA. Virology, 222: 31 – 42.

[87] Hoofnagle JH (1997). Hepatitis C: The clinical spectrum of diseases. Hepatology, 26: 155 – 205.

[88] International Consensus Conference on Hepatitis C (1999). Consensus Statement. Journal of Hepatology, 30: 956 - 961.

[89] Irshad M, Dhar I (2006). Hepatitis C virus core protein: an update on its molecular biology, cellular functions and clinical implications. Medicine principle and practice,15: 405 – 416.

[90] Ito S, Ito M, Cho MJ, Shimotohno K, Tajima K (1991). Massive sero epidemiological survey of hepatitis c virus. Journal of Cancer Resources, 82:1 – 3.

[91] J Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M (2006). Viral and therapentric control of IFN-beta promoter stimulator 1 during hepatitis c virus infection. National Academic Science USA, 103: 6001 – 6006.

[92] Jonas MM, (2002). Children with hepatitis C. Hepatology,36(1): 173 - 178

[93] Khan M, Jahan S, Khaliq S, Ijaz B, Ahmad W, Samreen B, Hassan S (2010). Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV – induced steatosis. Architechural virology, 155: 1735 - 1773.

[94] Kim AI, Saab S (2005). Treatment of hepatitis C. The American Journal of medicine, 118 (8): 808 – 815.

[95] Knodel RG, Conrad ME, Dienstag JL, Bell (1975). Etiological spectrum of post- transfusion hepatitis. Gastroenterology, 69: 1278 – 1285.

[96] Koa JH, Hwang YT, Chen PJ, (1996). Transfusion of hepatitis C virus between spouses: the important role of exposure duration. American Journal of Gastroenterology,91: 2087 - 2090.

[97] Lauer G. M, Walker BD (2001). Hepatitis C virus infection. New England Journal of Medicine, 345(1): 41 – 52.

[98] Law MG, Dore GJ, Bath N (2003). Modeling hepatitis c virus incidence, prevalence, and long-term sequence in Australia. International Journal of Epidemiolog, 32: 717 - 724.

[99] Lee P, Peng H, Gelbart T, Wang L, Bentler E. (2005). Regualtion of hepcidin Transcription by interleukin-1 and interleukin-6. National academics of Science, 102: 1906-1910.

[100] Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL (2002). Prognostic factors and early predictability of sustained viral response with peg interferon alfa - 2a (40KD). Journal of Hepatology, 37(4): 500 – 506.

[101] Lianping T. I, Michelle N. G, Lindila Awendila, Patrizia Maria Carrieri (2018). Hepatitis C virus infection and hospital related outcomes: a systematic review protocol. Journal of Clinical Pathology, 8(6): 110 - 118.

[102] Liu Hm, Gale M (2010) Hepatitis C virus Evasion from RIG-1-Dependent Hepatic Innate Immunity. Gastroenterology Resources and Practice, 2010:4 390.

[103] Lohmann V (2013). Hepatitis C virus RNA replication.Curriculum Top Microbiology and Immunology, 369: 167 – 198.

[104] Lopez Labrador FX, Ampurdanes S, Forns X, Castells A, Saz JC, Costa J (1997). Hepatitis c virus (HCV) genotypes in Spaniusb patients with HCV infection: relationship between genotype 1b, cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 27: 959 - 965.

[105] Lozach PY, Lortat-Jacob H, deLacroix de Lavvvalette A, Staropolic I, Foung S, Amara A (2003). Dc-SIGN and L-SIGN are highly affinity binding receptors for hepatitis virus glycoprotein E2. Journal of Biology and Chemistry, 278: 20358 – 20366.

[106] Machida K, Cheng KT, Sung VM, Lee KJ, Levine AM, Lai MM (2004). Hepatitis C virus infection activates the immunologic (type 11) isoform of nitric oxide synthase and thereby enhances DNA damage and mutation of cellular genes. Journal of Virology, 78: 8835 – 8843.

[107] Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM (2004). Hepatitis C virus induces a mutator phenotype: enhanced mutations of Immunoglobulin and protooncogenes. National Academic of Science, 101: 4262- 4267.

[108] Maecker HT, Levy S (1997). Normal lymphocyte development but delayed humoral immune response in CD81 – null mice. Experimental Journal of Medicine, 185: 1505 – 1510.

[109] Maecker HT, Todd SC, Levy S (1997). The tetraspanin super family: Molecular Facilitators. Journal of Federation of American Societies for Experimental Biology, 11: 428 - 442.

[110] Mahley RW, Ji ZS, (1999). Remnant hyproprotein metabolism. Key pathways involving cell-surface heparin sulphate proteoglycans and apolipoprotein E. Journal of Lipid Resources, 40: 1 – 16.

[111] Major M, Feinstone S (1997). The molecular virology of hepatitis C. Hepatology,25: 1527 - 1538

[112] Mansell CJ, Locarnini SA (1995). Epidemiology of hepatitis C in the East. Liver Diseases, 15: 15 - 32.

[113] Mao Clinic (2017). High White Blood Cell Count. Accessed: 16 September, 2017.

[114] Mao Weilin, Hu Ying, Lou Yufeng, Chen Yuemei, Zhang Juanwen (2015). Abnormal serum iron markers in chronic hepatitis B virus infection may be because of liver injury. European Journal of Gastroenterology and Hepatology, 27: 130 – 136.

[115] Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P (2001). Immunoglobulin gene mutations in hepatitis C virus – positive and hepatitis C virus – negative nodal marginal zone B-cells lymphoma. American Journal of Pathology, 159: 253 – 261.

[116] Margaretha Viljoen, Alida Maria Koots (2014). Acute phase proteins: Ferritin and Ferritin isoforms. https://www.researchgate.net/publication/221 917691. 53 – 184.

[117] Martinolt-Peignmx M, Boyer N, Le Breton V (2000). A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. Hepatology, 31:726 - 729.

[118] Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, Abrignani S, Uematsu Y (2002). Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology, 304: 187 –196.

[119] Mazzaro C, Tirelli U, Pozzato G (2005). Hepatitis C virus and non-Hodgkin lymphoma 10 years later. Digestive Liver Diseases, 37: 219 – 226.

[120] McHutchison JG, Gordon SC, Schiff ER, Shiffman Ml, Lee WM, Rustgi VK (1998). Interferon-alpha 26 alone or in combination with ribavirin as initial treatment for chronic hepatitis c. New England Journal of Medicine 352: 1426 - 1432

[121] McQuillan GM, Goa F, Moyer LA, Kaslow RA, Margolis HS (1999). The prevalence of hepatitis C virus in the United States. New England Journal of Medicine, 341:556 – 562.

[122] Mcttutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ (2001). Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. Journal of Viral Hepatology, 8 (6): 414 – 420.

[123] Mee CJ, Harris HJ, Parguhar MJ, Wilson G, Reynolds G, Davis C, Van ISC, Balfe P (2009). Polarization restricts hepatitis c virus entry into HepG2 hepauna cells. Journal of Virology 83: 6211 - 6221.

[124] Meredits LW, Wilson GK, Fletcher NF, MCKeating JA (2012). Hepatitis c virus entry. Beyond receptors. Review of Medical Virology, 22:182 – 193.

[125] Mizokami M, Gojobani T, Ohba K, Ikeo K, Ge M, Ohno T, (1996). Hepatitis c virus types 7, 8 and 9 should be classified as type 6 subtypes. Journal of Hepatology, 24: 622 - 624.

[126] Moradpour D, Penin F (2013). Hepatitis C virus proteins: From structure to function. Curriculum Top Microbiology and Immunology,36: 113 – 142.

[127] Moyer V. A (2013). Screening for hepatitis C infection in adults: U.S Preventive Services Task Force recommendation statement. Annual International Journal of Medicine, 159(5): 349 –357.

[128] Muro K, Terpstra V, Green SR, Kondratenko N, Steinbery D, Quehenberger O (1997). Chatacterisation of CLA-!, a human homologue of rodent scavenger recptor bi, as a receptor for high density hipoprotein and apoptotic thynocyes. Journal of Biological Chemistry, 272: 518 - 520.

[129] Mutimer D. J., Olomu A., Skidmore N (1994). Viral Hepatitis in Nigeria, Sickle Cell Diseases and Commercial Blood Donors. Journal of Medicine, 87: 407 - 411.

[130] National Institute of Health Consensus Development Conference Panel (1997). Statement on Management of hepatitis C. Hepatology,26 (1): 2 – 10.

[131] National Institutes of Health Consensus Development Conference Statement (2002). Management of hepatitis c. Gastroenterology 123(6): 2081 – 2099.

[132] National Pharmaceutical Services (2018). Hepatitis C virus management. 1 – 6.

[133] Negro F, Forton D, Crax A, Sulkowski MS, Feld JJ, Manns MP (2015). Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology, 149: 1345 – 1360.

[134] Nemeth E, Rivera S, Gabayan V, Killer C, Taudof S, Pederson B.K, Ganz T. (2004). IL-6 mediates poferraemia of inflammatory by inducing the sysnththeis of the iron regulating hormone hepcidiri. Journal of clinical investigation 113:1271-1276.

[135] Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donvan A, Ward DM (2004). Hepcidin regulates cellular iron efflux by binding to fero protein and inducing its internalization. Science 306: 2090 - 2093.

[136] Nemeth E, valore E.V, Territo M, Schiller G, Lichtenstein A, Ganz T. (2003). Hepcidin, a putative mediator of anaemia of inflammation, is a type II acute-phase protein. Blood 101:2461-2463.

[137] Neumann AU, Lam NP, Dahari H (1998). Hepatitis C viral dynamics in vivo and antiviral efficacy of interferon-alpha therapy. Science,282:103 – 107.

[138] Neumann-Haefelin C, Thimme R (2013). Adaptive immune responses in hepatitis c virus infection. Curriculum Top Microbiology Immunology, 369: 243 - 262.

[139] New Jersey Department of Health and Senior Services (2010). Hepatitis C:Communicable Disease Service Mannual. http://www.state.nj.us/health/cd/f_hepac.htm. June 9, 1 – 11.

[140] Ngugen Mh, Keeffe EB (2004). Epidemiology and treatment outcomes of patients with chronic hepatitis c and genotypes 4 to 9. Review of Gastroenterology Disorder,4:14 – 21.

[141] Nicolas G, Ghauwt C, Viatte L, Danan JL, Bigard X, Devause I, Beaumont C. (2002). The gene encoding the iron regulatory peptide hepaidive is regulated by anaemia, hypoxia, and inflammation. Journal of clinical investigation, 110:1037-1044.

[142] Niepmann M (2013). Hepatitis C virus RNA translation. Curriculum Top Microbiology and Immunology,369: 143 – 166.

[143] Nishioka SA, Gyorkos TW, Collect JP (2002). Tattooing and risk for transfusion transmitted diseases. Epidemiology of infectious disease, 128:63 – 71.

[144] Nwankiti O. O, Ndako J. A, Echeonwu G. O, Olabode A. O, Nwosuh C. L, Onovoh E. M (2009). Hepatitis C virus infection in apparentenly healthy individuals with family history of diabetes in Vom, Plateau state Nigeria. Journal of Virology, 6(1): 110.

[145] Obienu O, Nwokediuko S, Malu A, Lesi F (2011). Risk factors for Hepatitis c virus Transmission Obscure in Nigeria patients. Gastroenterology Research and Practice,4: 15 – 25.

[146] Ohgami RS, Campagna DR, McDonald, Fleming MD (2006). The steak proffering are metalloreductases. Blood, 108: 1388-1394.

[147] Ohkoshi S. A, Yoshimura S, Yamamoto M, Yano S, Kurita K, Yamazaki Y.H, Aoki S, Yamagiwa H (2008). “Successful treatment with lamivudine may correlate with reduction of serum ferritin levels in the parents with chronic hepatitis and liver cirrhosis type B”. International Hepatology, 2(3): 382 – 387.

[148] Ohshina S, Komatsu M, Nakane K (2000). Latrogenic Gb virus c/hepatitis G virus infection in an area endemic for hepatitis c virus. Journal of Hospital Infection,44: 179 - 185.

[149] Ojule Ac, Akani CI, Opurum HC (2008). Sero-prevalence of hepatitis c antibodies in pregnant women in Port Harcourt, Nigeria. Port Harcourt Medical Journal,3(1): 55 - 61.

[150] Okonkwo I, Adepoju A, Okerentungba P, Nwanze J, Onoh C (2005). Detection of hepatitis C virus (HCV) antibody among children in Ibadan, South-Western Nigeria. Journal of Medical and Health Sciences, 11:1 – 8.

[151] Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y, Okita K (1999). Differences in hyperviable region I quasi species of hepatitis C virus in human serum, peripheral blood mononuclear cells, and livers. Haematology,29:217 – 222.

[152] Oni AO, Harrison TJ (1996). Genotypes of Hepatitis C virus in Nigeria. Journal of Medical Virology andHepatology, 49: 178 – 186.

[153] Osaki Yuko, Nishikawa Hiroki (2015). Treatment for hepatocellular carcinoma in Japan over the last decades: Our experience and published work view. Hepatology Research, 45 (1): 59 –74.

[154] Paganelli MO, Grossi AB, Dores-Silva PR, Borges JC, Cardoso DR, Skibsted LH (2016). Limited proteolysis of myoglobin opens channel in ferochelatase-globin complex for iron to iron transmetallation. Food chemical 210: 491 - 499

[155] Palitzsch KD, Hottentrager B, Schlottmann K (1999). Prevalence of antibodies against hepatitis c virus in the adult German population. European Journal of Gastroenteroloogy and Hepatology, 11:1215 – 1220.

[156] Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D (2000). Standardization of Hepatitis C virus RNA Quantification. Hepatology,32(3): 654 –659.

[157] Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F (2007). The hepatitis C virus core protein of genotypes 3a and 1b down regulates insulin receptor subtract 1 through genotype specific mechanisms. Hepatology, 45: 1164 – 1171.

[158] Perlemuter G, Sabile K, Letteron P, Vona G, Topilco K, chretein Y, Koike K, Pessayre D, Chapman J, Barba G (2002). Hepatitis C virus care protein inhibits microsomal-triglyceride transfer protein activity and very low density hiporotein secretion: a model of viral-related steatosis. Journal of Federation of American Societies for Experimental Biology, 16: 185 - 194.

[159] Peters MG, terrault NA, (2002). Alcohol use and hepatitis C virus. Hepatology, 36(5): 1717 – 1722.

[160] Pietrangelo A (2007). Haemochromatosis: an endocrine liver disease. Hepatology, 46: 1291 – 1301.

[161] Pietrangelo A, Montosi G, Garutic C (2002). Iron-induced oxidants stress in nonparendymal liver cells: mitochondrial derangement and fibrosis in acutely iron- dosed gerbils and its prevention by silybin. Journal of Bio-engineering,34: 67 – 79.

[162] Polaris Observatory HCV Collaboration (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study. Lancet Gastroenterology and Hepatology, 2:161 – 176.

[163] Policeman S, Zhang J, Bariband F, Chen Z, Leslie GJ, Lin G, Graneilli Piperno A, Doms RW (2003). Hepatitis c virus glycoproteins interact with DC-SIGN and DC-SIGNR. Journal of Virology, 77: 4070 - 4080.

[164] Pouilot R, Lachenal G, Pybus OG, Rousset D, Njoum R, (2008). Variable epidemic histories of hepatitis c virus genotype 2 infection in West Africa and Cameroon. Infectious Genetic Evolution, 8:676 - 681.

[165] Poynard T, Bedosossa P, Opolon P (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet,349: 825 – 882.

[166] Poynard T, Marcelliri P, Lee SS (1998). Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet, 352: 1426 – 1432.

[167] Pra D, Franke SI, Henrigues JA, French M (2002). Iron and genuine stability: An update. Mutation Resolution,733: 92 – 99.

[168] Price L, Kowdley KV (2009). The role of iron in the pathophysiology and treatment of chronic hepatitis C. Canadan Journal of Gastroenterology, 23: 822 – 828.

[169] Puro V, Petrosillo N, Ippolito G, (1995). Italian Study Group on occupational risk of HIV and other blood borne infections. Risk of hepatitis C seroconversion after occupational exposures in health care workers. American Journal of Infectious Control, 23: 273 - 277.

[170] Puro V, Petrosilo N, Ippolito G, Aloisi MS, Boumis E, Rava L (1995). Occupational hepatitis c virus infection in Italian health care workers. American Journal of Public Health, 85:1272 – 1275.

[171] Recalcati S, Pometta R, Levi S, Conte D, Cairo G (1998). Response of monocyte iron regulatory protein activity in inflammation: abnormal behavior in genetic haemochromatosis. Blood, 91: 2563 – 2572.

[172] Rivas-Estilla Am, Cordero-Perez P, Trujillo- Murillo Kdel C, Ramons-Jimenez J, Chan- Lopez (2008). Genotyping of hepatitis c virus (HCV) in infected patients from North East Mexico. Annual Hepatology, 7:144-147.

[173] Robertson B, Myers G, Howard C (1998). Classification, nomenclature and data base development for hepatitis C virus (HCV) and related viruses: Proposals for standardization. Architectural virology, 143: 2493 – 2503.

[174] Roccasecca R, Ansuini H, Vitelli A, Scarcelli E, Acali S, Pezzanera M (2003). Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hyperviable regions 1 and 2. Journal of virology, 77: 1856 – 1867.

[175] Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadric R, Male PJ, Negro F (2001). Liver Steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology, 39:119 – 124.

[176] Rushton D. H, Barth J. H (2010). What is the evidence for gender differences in ferritin and haemoglobin? Critical Review on Oncology and Haematology, 73: 1 –9.

[177] Russo V, Rago A, Papa AA, Nigro G (2016). Electrocardiographic presentation, cardiac arrhythmias, ad their management in B- Thalassaemia major patients. Annual Noninbasive Electrocardiology, 21: 335 – 342.

[178] Saito T, Owne DM, Jiang F, Marcotrigiano J, Gale M (2008). Innate immunity induced by composition dependent RTG-1 Recognition of hepatitis C virus RNA. Nature, 454: 523 - 527.

[179] Scarselli E, Ansuini H, cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C (2002). The human scavenger receptor class B type 1 is a novel candidate receptor for the hepatitis C virus. Journalof European Molecular Biology Organization, 21: 5017 - 5025.

[180] Schoggins JW, Rice CM (2010). Interferon- Stimulated genres and their antiviral effector functions. Curriculum opinion virology, 1: 519 - 525

[181] Seeff LB(1995). Natural history of viral hepatitis, type c. Seminar on Gastrointestinal Disorder, 6:20 – 27.

[182] Sehmus Olmez, Mehmet Aslan, Bunyamin Saritas,Mehmet Suat Yancin, Adnan Tas (2016). Serum ferritin levels in patients with Hepatitis B virus and hepatitis D virus – related cirrhosis. Acta Medical Mediterranea, 32: 1813.

[183] Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, poupou RL (2001). Hepatitis C virus induced hypobetalipoproteinaemia: a possible mechanism for steatosis in chronic hepatitis C. Journal of Hepatology, 34: 428 - 434.

[184] Shan Ying, Richard Lambrecht W, Herbert Bonkovsky L (2005). Association of Hepatitis C Virus Infection with Serum Iron Status: Analysis of Data from the third National Health and Nutrition Examination Survey. Clinical Infectious Diseases, 40: 834 – 841.

[185] Shepard CW, Finelli L, Alter MJ (2005). Global epidemiology of hepatitis C virus infection. Lancet Infectious Disease,5(9): 558 – 567.

[186] Sheyinn Z, Jatau ED, Mamman Ai, Randawa Aj, Bigwan IE (2012). Detection of Hepatitis c virus amongst pregnant women in Kaduna Sate, Nigeria. Wudpecker Journal of Medical Sciences, 1(2): 012 - 015.

[187] Shi ST, polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM (2002). Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apoplipo proteins. Virology, 292: 198 - 210.

[188] Shih Hong-Mou, Wu Chih-Jen, Lin Shuei- Liong (2018). Physiology and Pathophysiology of renal erythropoietin producing cells. Journal of the Formosan Medical Association, 117: 955 – 963.

[189] Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K (2004). Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology, 126:840 – 848.

[190] Silva P, Kouyoumjian, Hiam Chemaitelly, Laith J, Abu-Raddad (2018). Characterizing hepatitis c virus epidemiology in Egypt: Systematic reviews, eta-analyses, and meta- regressions. Scientific Reports,8:1661.

[191] Stanaway JD (2016). The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study. Lancet, 388: 1081 – 1088.

[192] Stein J, Dignass A. U (2013). Management of iron deficiency anaemia in inflammatory bowel disease – a practical approach. Annual Gastroenterology, 357: 104 – 113.

[193] Taher AT, Musallam KM, Inati A (2009). Iron overload. Consequences, assessment, and monitoring. Hemoglobin, 33(1): 46 – 57.

[194] Takaki A, Wiese M, Maertens G (2000). Cellular immune responses persist and immoral responses decrease. Two decades after recovery from a single source outbreak of hepatitis C. National Medical, 6: 578 – 582.

[195] Tanaka T, Kato N, Cho M, Shimotohno K (1995). A novel sequence found at the 3 terminus of hepatitis c virus genuine. Biochemistry and Biophysics, 215: 744 – 749.

[196] Theil EC (1987). “Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms”. Annual Review of Biochemistry,56(1): 289 – 315.

[197] Theil, Elizabeth C (2012). “Ferritin protein nanocages – the story”. Nanotechnology perceptions,8: 7 – 16.

[198] Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ (2008). Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology, 47: 17 – 24.

[199] Tokita H, Okamoto H, Luengrojanakul P, Vareesangthip K, Chainuvati T, Lizuka H (1995). Hepatitis C virus variants from Thailand classifiable into five new genotype in the sixth, seventh and ninth major genetic groups. Journal of General Virology, 76: 2329 – 2335.

[200] Torti FM, Torti SV (2002). “Regulation of ferritin genes and rotein”. Blood,99(10): 3505 – 3516.

[201] Tsang PS, Trinh H, Garcia RT, Phan JT, Ha NB, Nguyen H, Nguyen K, Keeffe EB, Nguyen MH (2008). Significant Prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clinical Gastroenterology and Hepatology, 6(5): 569 – 574.

[202] Ugbebor O, Aigbirior M, Oazuwa F (2011). The prevalence of hepatitis B and c viral infections among pregnant women. North American Journal of Medical Science,3: 238 – 241.

[203] Urbano S, Tom Denee R, Nonis Turner G, George Wan J, Alan Morrison, Anna Kaufman S (2016). Conceptual Framework for Outcomes research studies of hepatitis C: an analytical review.Infection and Drug Resistance, 9: 101 – 117.

[204] Valtuile R, Fernandez J.L, Berridi J (1988). Evidence of hepatitis C virus passage across dialysis membrane. We phone,80: 194 - 196.

[205] Viveiros Andre, Finkenstedt Armin, Schaefer Benedikt, Mandorfer Mattias, Scheiner Bernhard, Lerner Konrad (2018). Transferrin as a predictor of survival in cirrhosis. Liver Transplantation, 24: 343 – 351.

[206] Vrielink H, Reesink HW, Vanden Burg PJ (1997). Performance of three generations of anti-hepatitis C virus enzyme -linked immunosorbent assays in donors and patients. Transfusion, 37: 845 - 849.

[207] Weiner AJ, Brauer MJ, Roseblatt J, Richman KH, Tung Z, Crawford K, (1991). Variable and hyperviable domains are found in the regions of corresponding to the flavivins envelope and NSI proteins and the pestivins envelope glycoproteins. Virology, 180: 842 – 848.

[208] Winter W. E, Bazydlo L. A, Harris N.S (2014). The molecular biology of human iron metabolism. Laboratory medicine, 45: 92 – 102.

[209] World Health Organization (2016). Hepatitis C: Fact Sheet.http:llwww.who.int/mediacentre /factsheet /fs164/en/(cited 6 July 2016).

[210] Wrighting D.M, Andrews N. C. (2006). Interleukin-6 induces hepcidin expression through STAT 3. Blood,108:3204-3209.

[211] Yano M (1996). The long-term pathological evolution of chronic hepatitis C. Hepatology, 23(6): 1334 - 1340.

[212] Yoon H, Kim Y. S, Lee J. H, Gi M. Y, Cha J. A, Seong J. M (2018). Gender difference in the relationship between the ferritin and homeostasis model assessment of insulin resistance in non-diabetic Korean adults. PLoS ONE, 13(6): 1 – 12.

[213] Young R. A, Davis R.W (1983). Efficient isolation of genes by using antibody probes. Natural Academic Science USA, 80: 1194 – 1198.

[214] Zeisel MB, Felmlee DJ, Baumert TF (2013). Hepatitis C virus entry. Curriculum Top Microbiology Immunology,369: 87 – 112.

[215] Zignego A. L, Giannelli F, Marrocchi M. E, Mazzocca A, Ferri C, Giannini C (2000). T(14;18) translocation in chronic hepatitis C virus infection. Hepatology, 31: 474 – 479.

[216] Zinkernaged RM, Haenseleer E, Leist T, cerny A, hengartner H, Althange A (1986). T cell- mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class 1-restricted virus specific cytotoxic T cells as a physiological correlate of the 51cr-release assay? Journal of Experimental Medicine, 164: 1075 - 1092.

[217] Zou DM, Sun WL (2017). Relationship bwteen Hepatitis C virus infection and iron overload. Chinese Medical Journal, 130: 866 – 871.

[218] Zou S, Tepper M, Elsaadany S (2000). Prediction of hepatitis c burden in Canada. Canada Journal of Gastroenterology,14: 575 – 580.

@article{1710277,
      author = {Okereke, Chibueze Aphogu, Prof. Ufelle Silas},
      title = {Evaluation of Iron Biomarkers and Haematological Variables in Asymptomatic Individuals Infected by Hepatitis C Virus in Ebonyi State, Nigeria},
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {9},
      number = {2},
      pages = {933-968},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1710277.pdf},
      abstract = {Alteration in iron biomarkers is a common finding in viral hepatitis. The knowledge of the frequency of the haematological abnormalities in patients with hepatitis C virus (HCV) infection will support the need for this indispensable tool in the investigation of infectious disease. This work was designed to investigate the changes in iron biomarkers and haematological variables of asymptomatic HCV infected individuals. Ethical clearance was obtained from Health Research and 	Ethical Committee of the University of Nigeria Teaching Hospital, Ituku/Ozalla. One hundred and thirty individuals with asymptomatic HCV infection were drawn from thirteen Local Government Areas of Ebonyi State, consisting of 60 males and 70 females. Informed consent were obtained from them after pretest counseling. Blood sample (8.0ml) was collected aseptically from each individual using a sterile syringe and needle and3.0ml was placed in ethylene diamine tetra-acetic acid and 5.0ml in plain container. The analysis of the samples were done in Marylmas Research and Diagnostic Laboratory in Abakaliki using standard operating procedure and automation using automated machine, sysmex XT4000i (United State of America) for complete blood count. The significant (p < 0.05) results of male asymptomatic HCV infected individuals were increased ferritin (644.35 ? 98.42?g/L), increased total iron binding capacity (TIBC) (88.51 ?  4.68?mol/L), increased to transferrin (3.54 ?  0.91g/L) , decreased total iron (15.81? 8.94?mol/L) and decreased transferrin saturation (17.82 ? 10.21%) compared to control: ferritin (227.67 ? 43.95?g/L), TIBC (67.00 ? 4.10?mol/L), transferrin (2.68 ? 0.16g/L), total iron (28.33 ? 1.03?mol/L) and transferrin saturation (42.67 ? 1.37%). Their significant (p < 0.05) results for complete blood count were increased total white blood Cell (TWBC) (4.78 ? 1.54 x 109/L), increased red blood cell (RBC) (5.23 ? 0.75 x 1012/L), increased haemoglobin (15.34 ? 2.30g/dL), increased haemotocrit (42.34 ? 5.25%) compared to control :TWBC (3.33 ? 0.21 x 109/L), RBC (4.33 ? 0.41 x 1012/L), haemoglobin (13.33 ? 0.49g/dL) and haemotocrit (35.80 ? 2.06%). The significant (p < 0.05) results of female asymptomatic HCV infected individuals were increased ferritin (502.78 ? 350.14?g/L), increased TIBC (89.30 ? 11.07 ?mol/L), increased transferrin (3.57 ? 0.44%), decreased total iron (13.43 ? 7.66?mol/L), decreased transferrin saturation (14.78 ? 7.79%) compared to control: ferritin (82.67 ? 19.13 ?g/L), TIBC (53.33 ? 2.73?mol/L), transferrin (2.13 ? 0.11g/L), total iron (21.33 ? 1.37?mol/L), transferrin saturation (40.00 ? 0.89%). Their significant (p < 0.05) results for complete blood count were increased TWBC (5.53 ? 1.83 x 109/L), increased RBC (5.28 ? 1.12 x 1012/L), increased haemoglobin (15.20 ? 3.36g/dL), increased haemotocrit (41.39 ? 8.23%) compared to control TWBC (3.40 ? 0.32 x 109/L), RBC (3.81 ? 0.77 x 1012/L), haemoglobin (11.33 ? 0.40g/dL), haemotocrit (30. 87 ? 1.36%). The results suggested that HCV infection modulates iron metabolism and homeostasis in host hepatic cell. The elevated serum ferritin acts as a marker of inflammation and infection in these individuals. The severity and progression of liver diseases depends on the levels of serum ferritin and transferrin. The HCV infection appears to have little effect on the haematological variables in the study.},
      month = {August},
  }